Abstract
Collection and storage of the clinical samples are crucial factors in the metabolomic workflows. However, with the expansion of metabolomics into the clinical domain and towards the large field studies in particular, the high sampling/storage standards practiced in the tightly controlled hospital environment cannot always be guaranteed. Thus, if the samples are exposed to suboptimal conditions and their integrity is compromised should they be discarded? Or such samples retain physiologically relevant information and can be of use? To explore the options we analyzed 117 urine samples that were collected under two different conditions. Part of the samples were collected within a clinical setting under optimal conditions, another part by patients at home and shipped to the hospital by mail. All samples were analyzed by liquid chromatography–mass spectrometry (LC–MS) and proton nuclear magnetic resonance (1H NMR) spectroscopy. Multivariate modelling revealed clear differences between the two sampling conditions for both LC–MS and 1H NMR data sets. However, the differential metabolites appeared to be platform-specific, which clearly emphasizes the complementary nature of both techniques. The analysis of the samples that were exposed to suboptimal conditions revealed that age and body mass index remain as dominant traits of the metabolic profile, although their influence was stronger for LC–MS data. In conclusion, although it is important to ensure adequate sample collection and storage conditions, urine samples that do not fulfil these criteria still retain valuable physiological information and as such thus they could be of use for metabolomic studies when no alternative is available.
Similar content being viewed by others
References
Gupta A, Bansal N, Houston B (2012) Expert Rev Mol Diagn 12:361–369. doi:10.1586/erm.12.27
Beckonert O, Keun HC, Ebbels TM, Bundy J, Holmes E, Lindon JC, Nicholson JK (2007) Nat Protoc 2:2692–2703. doi:10.1038/nprot.2007.376
Holland NT, Pfleger L, Berger E, Ho A, Bastaki M (2005) Toxicol Appl Pharmacol 206:261–268. doi:10.1016/j.taap.2004.10.024
Tuck MK, Chan DW, Chia D, Godwin AK, Grizzle WE, Krueger KE, Rom W, Sanda M, Sorbara L, Stass S, Wang W, Brenner DE (2009) J Proteome Res 8:113–117. doi:10.1021/pr800545q
Lodi A, Tiziani S, Khanim FL, Gunther UL, Viant MR, Morgan GJ, Bunce CM, Drayson MT (2013) PLoS One 8:e56422. doi:10.1371/journal.pone.0056422
Voet NB, Bleijenberg G, Padberg GW, van Engelen BG, Geurts AC (2010) BMC Neurol 10:56. doi:10.1186/1471-2377-10-56
Nevedomskaya E, Mayboroda OA, Deelder AM (2011) Mol BioSyst 7:3214–3222. doi:10.1039/c1mb05280b
Pacchiarotta T, Hensbergen PJ, Wuhrer M, van Nieuwkoop C, Nevedomskaya E, Derks RJ, Schoenmaker B, Koeleman CA, van Dissel J, Deelder AM, Mayboroda OA (2012) J Proteomics 75:1067–1073. doi:10.1016/j.jprot.2011.10.021
Nevedomskaya E, Derks R, Deelder AM, Mayboroda OA, Palmblad M (2009) Anal Bioanal Chem 395:2527–2533. doi:10.1007/s00216-009-3166-1
Smith CA, Want EJ, O’Maille G, Abagyan R, Siuzdak G (2006) Anal Chem 78:779–787. doi:10.1021/ac051437y
Coron A, Vanhamme L, Antoine JP, Van Hecke P, Van Huffel S (2001) J Magn Reson 152:26–40. doi:10.1006/jmre.2001.2385
Smilde AK, van der Werf MJ, Bijlsma S (2005) van der Werff-van der Vat BJ, Jellema RH. Anal Chem 77:6729–6736. doi:10.1021/ac051080y
Rasmussen LG, Savorani F, Larsen TM, Dragsted LO, Astrup A, Engelsen SB (2011) Metabolomics 7:71–83. doi:10.1007/s11306-010-0234-7
Sweatman BC, Farrant RD, Lindon JC (1993) J Pharmaceut Biomed 11:169–172. doi:10.1016/0731-7085(93)80138-Q
Lauridsen M, Hansen SH, Jaroszewski JW, Cornett C (2007) Anal Chem 79:1181–1186. doi:10.1021/Ac061354x
Maher AD, Zirah SF, Holmes E, Nicholson JK (2007) Anal Chem 79:5204–5211. doi:10.1021/ac070212f
Saude EJ, Sykes BD (2007) Metabolomics 3:19–27. doi:10.1007/s11306-006-0042-2
Crockford DJ, Holmes E, Lindon JC, Plumb RS, Zirah S, Bruce SJ, Rainville P, Stumpf CL, Nicholson JK (2006) Anal Chem 78:363–371. doi:10.1021/Ac051444m
Crockford DJ, Maher AD, Ahmadi KR, Barrett A, Plumb RS, Wilson ID, Nicholson JK (2008) Anal Chem 80:8353. doi:10.1021/Ac801996w
Balog CI, Meissner A, Goraler S, Bladergroen MR, Vennervald BJ, Mayboroda OA, Deelder AM (2011) Mol BioSyst 7:1473–1480. doi:10.1039/c0mb00262c
Singer BH, Utzinger J, Ryff CD, Wang Y, Holmes E (2007) Exploiting the potential of metabonomics in large population studies: three venues. In: Lindon JC, Nicholson JK, Holmes E (eds) The handbook of metabolomics. Elsevier, Amsterdam
Kochhar S, Jacobs DM, Ramadan Z, Berruex F, Fuerholz A, Fay LB (2006) Anal Biochem 352:274–281. doi:10.1016/j.ab.2006.02.033
Delanghe J, Speeckaert M (2014) Biochem Medica 24:89–104
Author information
Authors and Affiliations
Corresponding author
Additional information
Published in the topical collection Recent Developments in Clinical Omics with guest editors Martin Giera and Manfred Wuhrer.
Electronic Supplementary Material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Morello, J., Nevedomskaya, E., Pacchiarotta, T. et al. Effect of Suboptimal Sampling and Handling Conditions on Urinary Metabolic Profiles. Chromatographia 78, 429–434 (2015). https://doi.org/10.1007/s10337-014-2778-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10337-014-2778-6